Compare · ACHV vs ICCC

ACHV vs ICCC

Side-by-side comparison of Achieve Life Sciences Inc. (ACHV) and ImmuCell Corporation (ICCC): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ACHV and ICCC operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • ACHV is the larger of the two at $697.7M, about 7.5x ICCC ($92.8M).
  • ACHV has been more active in the news (6 items in the past 4 weeks vs 4 for ICCC).
  • ACHV has more recent analyst coverage (11 ratings vs 0 for ICCC).
MetricACHVICCC
Company
Achieve Life Sciences Inc.
ImmuCell Corporation
Price
-
-
Market cap
$697.7M
$92.8M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
1987
News (4w)
6
4
Recent ratings
11
0
ACHV

Achieve Life Sciences Inc.

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

ICCC

ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Latest ACHV

Latest ICCC